1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Karuna Upbeat On New Antipsychotic Mechanism Data

Phase III Studies Could Begin For The Combination Therapy Next Year

 
• By John Davis

Karuna Therapeutics’ top-line Phase II data for a combination of a centrally acting muscarinic agonist, xanomeline, and a peripherally acting muscarinic antagonist, trospium, were greeted with enthusiasm by investors and the Boston, MA-based biotech.  

Screen_Data
• Source: Shutterstock

Advances have been rare in the development of new medicines for psychosis and schizophrenia over past decades, so the reporting of “thrilling” top-line Phase II results for Karuna Therapeutics Inc.’s novel CNS muscarinic receptor-targeted KarXT (xanomeline/trospium) co-formulation has been greeted with some initial enthusiasm by investors.

This enthusiasm was linked to a four-fold increase in Karuna’s share price, from $17.6 to $96

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.